Cava, Hims & Hers Health, and Sweetgreen have more than doubled in 2024. Cava and Sweetgreen should continue to benefit from the return to in-office workplaces....
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new...
There are valid points in the short report, but it may present a buying opportunity for long-term investors....
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space....
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'....
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock....
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes...
Consumer spending on healthcare and restaurants is resilient in a range of economic environments. Hims & Hers is tapping into the potential of the lucrative telehealth market....
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day....
The telehealth company is offering innovative products at lower prices....
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB....